FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885822555> ?p ?o ?g. }

• W2885822555 endingPage "E238" @default.
• W2885822555 startingPage "E237" @default.
• W2885822555 abstract "To the Editor: The authors would like to thank the editors for the opportunity to further discuss the importance of our study, “Steroid Use Associated With Increased Odds of 30-Day Mortality in Surgical Patients With Metastatic Spinal Tumors in the Setting of Disseminated Disease”.1 We appreciate the rigorous critique of our paper outlined in the letter to the editor,2 as we always champion rigorous debate and scientific discourse, and are glad to address the concerns raised therein. The critiques raised actually highlight the importance and value of our study. Most striking is our specialty's continued reliance on studies with non-surgical cohorts, from which we externally generalize the results and make decisions regarding the utility of steroids for our surgical patients.3-8 Our study, limited to patients having received surgical intervention as a part of the treatment of their disease, provides an important insight into how steroids may affect this patient population. The critique specifically discusses a review article by expert spinal surgeons, which cites a study by Sorenson et al8 regarding the effect of steroid use on 1-yr ambulatory status in patients with metastatic spinal cord compression. However, the review by the expert spinal surgeons,9 and thus the critique which propagates the information provided in the review, with all due respect, are inaccurate. The review, authored by Kumar et al9 quotes the Sorenson study as follows: “…Sorensen and colleagues, where the use of high-dose dexamethasone (96 mg/d) resulted in a statistically greater percentage of patients surviving with ambulatory function at 1 year”. The critique promulgates the inaccurate information further by stating, “Sorensen et al. published almost 25 years ago a single-blinded randomized trial comparing high dose dexamethasone (96 mg IV bolus followed by 24 mg every six hours tapered over 10 days) plus radiation to no steroids plus radiation in patients with MSCC, finding significantly higher rates of ambulation at 1 year and yet no increase in mortality in favor of steroids”.9 However, if you read the original manuscript, you will see that the 1-yr survival with ambulatory function was highly statistically insignificant between the 2 groups (steroid group n = 8 (30%), non-steroid group n = 6 (20%), chi-squared = 0.71, P = .4).7 The critique propagates the misunderstanding purported by the review by Kumar et al9 and thus provides no support for the letter's argument. Additionally, we would hesitate to use the phrase “gold standard” for a medication for which a recent Cochran review10 found there to be no evidence to suggest there is any difference between the actual usage of steroids compared to no steroids on outcomes in metastatic spinal cord compression patients. While it may be considered common practice, and indeed it is common practice at the authors’ institutions to use steroids in patients presenting with neurological symptoms, the phrase “gold standard” does not necessarily apply in this instance where there is no actual strong data of their benefit. Regarding the concern of the steroid variable itself brought up by the letter,2 we adequately discussed the limitations of this variable in the manuscript and in the supplemental material,1 highlighting the risk of misclassification of exposure bias, and the lack of specific details regarding indication, dose, and length of administration. This hardly represents a fundamental flaw nor does it impart irrelevance to our study. There is precedent in the literature, including Neurosurgery, regarding this variable representing steroid use.11 Additionally, the claim that this variable may represent patients which have been on steroids for other diseases, is just as likely to be true as the converse, that all of these patients captured by steroid variable are receiving corticosteroids for the exact purpose we’re discussing, metastatic spinal cord compression, particularly since our cohort consists of surgical patients only. Furthermore, we never implied nor suggested physicians should not use steroids. Steroids may have a very important role in the management of patients with spinal metastasis presenting with neurological symptoms due to cord compression. We were very cautious not to overstate the conclusions which can be drawn from this study design. We stated there was a significant association identified between steroid use and mortality in this particular setting and this particular patient type which warrants further investigation. We never stated, nor eluded to the letter's claim that our conclusion “suggests that administration of steroids upon initial presentation of motor weakness in patients with MSCC increases the risk of mortality”. Our study was not designed, nor intended to confirm or deny this claim. It is out of place regarding our findings and representation of the data thereof. One should refrain from overstating conclusions in a negative light in order to marginalize or discredit a study's results. We have identified a significant association between steroid use and mortality in the data, which warrants further investigation in a controlled setting. Only then should judgment be passed. Additionally, we have identified a critical knowledge gap (steroid use in surgically managed patients) that should be addressed in our field given how frequently and how commonly this medication is prescribed to our patients. We again thank the authors for their interest in our article and the editors of Neurosurgery for this opportunity to discuss our research. Disclosures Dr Mehta provides consulting services for Spinal Elements and receives teaching travel funding from Globus. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article." @default.
• W2885822555 created "2018-08-22" @default.
• W2885822555 creator A5061166900 @default.
• W2885822555 creator A5069841841 @default.
• W2885822555 creator A5076123107 @default.
• W2885822555 date "2018-12-11" @default.
• W2885822555 modified "2023-10-17" @default.
• W2885822555 title "In Reply: Steroid Use Associated With Increased Odds of 30-Day Mortality in Surgical Patients with Metastatic Spinal Tumors in the Setting of Disseminated Disease" @default.
• W2885822555 cites W1973036127 @default.
• W2885822555 cites W2002643576 @default.
• W2885822555 cites W2029139723 @default.
• W2885822555 cites W2062550356 @default.
• W2885822555 cites W2163235609 @default.
• W2885822555 cites W2170891429 @default.
• W2885822555 cites W2681659520 @default.
• W2885822555 cites W2789344088 @default.
• W2885822555 cites W3141908569 @default.
• W2885822555 cites W4322703419 @default.
• W2885822555 doi "https://doi.org/10.1093/neuros/nyy582" @default.
• W2885822555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30535240" @default.
• W2885822555 hasPublicationYear "2018" @default.
• W2885822555 type Work @default.
• W2885822555 sameAs 2885822555 @default.
• W2885822555 citedByCount "0" @default.
• W2885822555 crossrefType "journal-article" @default.
• W2885822555 hasAuthorship W2885822555A5061166900 @default.
• W2885822555 hasAuthorship W2885822555A5069841841 @default.
• W2885822555 hasAuthorship W2885822555A5076123107 @default.
• W2885822555 hasBestOaLocation W28858225551 @default.
• W2885822555 hasConcept C126322002 @default.
• W2885822555 hasConcept C141071460 @default.
• W2885822555 hasConcept C143095724 @default.
• W2885822555 hasConcept C151956035 @default.
• W2885822555 hasConcept C177713679 @default.
• W2885822555 hasConcept C20387591 @default.
• W2885822555 hasConcept C2779134260 @default.
• W2885822555 hasConcept C2908647359 @default.
• W2885822555 hasConcept C512399662 @default.
• W2885822555 hasConcept C61434518 @default.
• W2885822555 hasConcept C71924100 @default.
• W2885822555 hasConcept C99454951 @default.
• W2885822555 hasConceptScore W2885822555C126322002 @default.
• W2885822555 hasConceptScore W2885822555C141071460 @default.
• W2885822555 hasConceptScore W2885822555C143095724 @default.
• W2885822555 hasConceptScore W2885822555C151956035 @default.
• W2885822555 hasConceptScore W2885822555C177713679 @default.
• W2885822555 hasConceptScore W2885822555C20387591 @default.
• W2885822555 hasConceptScore W2885822555C2779134260 @default.
• W2885822555 hasConceptScore W2885822555C2908647359 @default.
• W2885822555 hasConceptScore W2885822555C512399662 @default.
• W2885822555 hasConceptScore W2885822555C61434518 @default.
• W2885822555 hasConceptScore W2885822555C71924100 @default.
• W2885822555 hasConceptScore W2885822555C99454951 @default.
• W2885822555 hasIssue "3" @default.
• W2885822555 hasLocation W28858225551 @default.
• W2885822555 hasLocation W28858225552 @default.
• W2885822555 hasOpenAccess W2885822555 @default.
• W2885822555 hasPrimaryLocation W28858225551 @default.
• W2885822555 hasRelatedWork W1604293003 @default.
• W2885822555 hasRelatedWork W1604849300 @default.
• W2885822555 hasRelatedWork W2000811477 @default.
• W2885822555 hasRelatedWork W2349001406 @default.
• W2885822555 hasRelatedWork W2364829248 @default.
• W2885822555 hasRelatedWork W2365653098 @default.
• W2885822555 hasRelatedWork W2385612156 @default.
• W2885822555 hasRelatedWork W2766061861 @default.
• W2885822555 hasRelatedWork W3032220911 @default.
• W2885822555 hasRelatedWork W3045293259 @default.
• W2885822555 hasVolume "84" @default.
• W2885822555 isParatext "false" @default.
• W2885822555 isRetracted "false" @default.
• W2885822555 magId "2885822555" @default.
• W2885822555 workType "article" @default.